Background/Aims: The factors related to cerebrovascular complications in cerebral venous sinus thrombosis (CVST) are controversial. We focused on venous stasis and investigated its relationship with cerebrovascular complications in CVST. Methods: CVST patients between June 2013 and October 2016 were enrolled. Relationships between cerebrovascular complications, defined as cerebral venous infarction, intracerebral hemorrhage, or subarachnoid hemorrhage, and cerebrum venous stasis and other clinical information were retrospectively analyzed. Venous stasis was evaluated by the prominence of the veins on susceptibility-weighted imaging (SWI). The cerebrum was divided into 10 regions according to the venous drainage territories, and venous stasis was quantified by adding one point for venous prominence on SWI for each region (CVST SWI score). Results: All 5 cases in the noncomplicated group had a CVST SWI score of 0. The 3 patients with CVST SWI scores higher than 0 had cerebrovascular complications. The CVST SWI scores were higher in the complicated group than in the noncomplicated group (3.0 vs. 0, p = 0.010). Seizures were seen in all patients with complications and in none of the patients without complications (3 vs. 0, p = 0.018). Conclusion: Venous stasis evaluated by SWI can help predict cerebrovascular complications in CVST. A seizure is an important initial symptom that suggests cerebrovascular complications in CVST.

Keywords:
Cerebral venous thrombosis, Complications, Magnetic resonance imaging, Seizures, Susceptibility-weighted imaging, Venous stasis
1.
Zubkov AY, McBane RD, Brown RD, Rabinstein AA: Brain lesions in cerebral venous sinus thrombosis. Stroke 2009; 40:1509–1511.
2.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F: Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664–670.
3.
Kowoll CM, Kaminski J, Weiß V, Bösel J, Dietrich W, Jüttler E, Flechsenhar J, Guenther A, Huttner HB, Niesen WD, Pfefferkorn T, Schirotzek I, Schneider H, Liebig T, Dohmen C: Severe cerebral venous and sinus thrombosis: clinical course, imaging correlates, and prognosis. Neurocrit Care 2016; 25:392–399.
4.
Kato Y, Takeda H, Furuya D, Nagoya H, Deguchi I, Fukuoka T, Tanahashi N: Subarachnoid hemorrhage as the initial presentation of cerebral venous thrombosis. Intern Med 2010; 49:467–470.
5.
Lövblad KO, Bassetti C, Schneider J, Ozdoba C, Remonda L, Schroth G: Diffusion-weighted MRI suggests the coexistence of cytotoxic and vasogenic oedema in a case of deep cerebral venous thrombosis. Neuroradiology 2000; 42:728–731.
6.
Lövblad KO, Bassetti C, Schneider J, Guzman R, El-Koussy M, Remonda L, Schroth G: Diffusion-weighted MR in cerebral venous thrombosis. Cerebrovasc Dis 2001; 11:169–176.
7.
Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK, Xu Y, Neelavalli J, Haddar D, Reichenbach JR: Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22:439–450.
8.
Viallon M, Altrichter S, Pereira VM, Nguyen D, Sekoranja L, Federspiel A, Kulcsar Z, Sztajzel R, Ouared R, Bonvin C, Pfeuffer J, Lövblad KO: Combined use of pulsed arterial spin-labeling and susceptibility-weighted imaging in stroke at 3T. Eur Neurol 2010; 64:286–296.
9.
Coutinho JM, Gerritsma JJ, Zuurbier SM, Stam J: Isolated cortical vein thrombosis: systematic review of case reports and case series. Stroke 2014; 45:1836–1838.
10.
Leach JL, Fortuna RB, Jones BV, Gaskill-Shipley MF: Imaging of cerebral venous thrombosis: current techniques, spectrum of findings, and diagnostic pitfalls. Radiographics 2006; 26(suppl 1):S19–S43.
11.
Kawabori M, Kuroda S, Kudo K, Terae S, Kaneda M, Nakayama N, Iwasaki Y: Susceptibility-weighted magnetic resonance imaging detects impaired cerebral hemodynamics in the superior sagittal sinus thrombosis case report. Neurol Med Chir (Tokyo) 2009; 49:248–251.
12.
Tong KA, Ashwal S, Obenaus A, Nickerson JP, Kido D, Haacke EM: Susceptibility-weighted MR imaging: a review of clinical applications in children. AJNR Am J Neuroradiol 2008; 29:9–17.
13.
Ferro JM, Correia M, Rosas MJ, Pinto AN, Neves G: Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003; 15:78–83.
14.
Masuhr F, Busch M, Amberger N, Ortwein H, Weih M, Neumann K, Einhäupl K, Me-hraein S: Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. Eur J Neurol 2006; 13:852–856.
15.
Ferro JM, Canhão P, Bousser MG, Stam J, Barinagarrementeria F: Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008; 39:1152–1158.
16.
Kalita J, Chandra S, Misra UK: Significance of seizure in cerebral venous sinus thrombosis. Seizure 2012; 21:639–642.
17.
Willmore LJ, Sypert GW, Munson JV, Hurd RW: Chronic focal epileptiform discharges induced by injection of iron into rat and cat cortex. Science 1978; 200:1501–1503.
18.
Letourneau-Guillon L, Krings T: Simultaneous arteriovenous shunting and venous congestion identification in dural arteriovenous fistulas using susceptibility-weighted imaging: initial experience. AJNR Am J Neuroradiol 2012; 33:301–307.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.